Abstract Number: 0497 • ACR Convergence 2025
Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
Background/Purpose: To retrospectively evaluate drug survival and reasons for discontinuation of eight biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients using the Niigata…Abstract Number: 0480 • ACR Convergence 2025
Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate
Background/Purpose: Addition of a biologic disease-modifying antirheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) is recommended in patients with rheumatoid arthritis (RA) with inadequate response…Abstract Number: 0463 • ACR Convergence 2025
Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
Background/Purpose: Synovial tissue pathotype may indicate treatment response in RA, but synovial biopsies are not widely available. Synovial fluid (SF) is a promising surrogate. We…Abstract Number: 0445 • ACR Convergence 2025
GLP-1 Receptor Agonists Reduce Mortality and Cardiovascular Events in Patients with Rheumatoid Arthritis
Background/Purpose: Obesity significantly increases cardiovascular morbidity and mortality in rheumatoid arthritis (RA), yet effective strategies for managing obesity-related risks in this population remain limited. Glucagon-like…Abstract Number: 0379 • ACR Convergence 2025
Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study
Background/Purpose: Residual fatigue highlights an unmet prevalent1 need in rheumatoid arthritis (RA) patients despite achieving remission of disease activity according to activity indices (DAS28).We examine…Abstract Number: 0215 • ACR Convergence 2025
Impact of Global Review on Comorbidity Management in Inflammatory Arthritis Patients
Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), face elevated risk for comorbidities that complicate disease management. Although rheumatology societies…Abstract Number: 0147 • ACR Convergence 2025
Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations – PREST study
Background/Purpose: A total of 98.8% of French citizens are registered in the National Health Data System (SNDS), which includes claims data of all reimbursed health-related…Abstract Number: 0083 • ACR Convergence 2025
Confirmatory Factor Analysis of the Plutchik Suicide Risk Scale in Patients with Rheumatoid Arthritis
Background/Purpose: Prevalence of depression in RA patients ranging from 10% to 25%, making it the most common psychiatric disorder in this population. The Plutchik Suicide…Abstract Number: 0062 • ACR Convergence 2025
Neddylation as a Therapeutic Target in Autoimmune Arthritis: Evidence from SKG Mice
Background/Purpose: Neddylation, NEDD8 conjugating process, is a post-translational modification that plays a crucial role in regulating ubiquitination by targeting cullin (CUL)-ring E3 ubiquitin ligases. Our…Abstract Number: 2628 • ACR Convergence 2025
Calprotectin and Anti-CCP Antibodies Predict Development of Preeclampsia
Background/Purpose: Several systemic autoimmune diseases are associated with an increased risk of preeclampsia. Preeclampsia is a pregnancy complication characterized by new-onset hypertension after 20 weeks…Abstract Number: 2289 • ACR Convergence 2025
Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity in Patients with Rheumatoid Arthritis: A Pilot Study
Background/Purpose: Vagus nerve stimulation (VNS) has emerged as a potential therapeutic strategy for inflammatory diseases by modulating inflammatory reflex pathways. Transcutaneous auricular vagus nerve stimulation…Abstract Number: 2271 • ACR Convergence 2025
Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
Background/Purpose: Early use of targeted therapy (TT), such as anti-tumor necrosis factor (anti-TNF) biologics, show improved outcomes for RA1, but costs often limit access. Biosimilars,…Abstract Number: 2255 • ACR Convergence 2025
Diagnostic Accuracy of Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Background/Purpose: Anti-carbamylated protein antibodies (anti-CarP Ab) are emerging serologic markers in rheumatoid arthritis (RA). Anti-CarP Ab has a controversial diagnostic utility in RA but may…Abstract Number: 2238 • ACR Convergence 2025
Impact of Type 2 Diabetes on Cardiovascular and Renal Outcomes in Rheumatoid Arthritis: Insights from a Large-Scale Multi-Center Analysis
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular risk, but the additional impact of type 2 diabetes mellitus (T2DM) on the cardiorenal outcomes in…Abstract Number: 2191 • ACR Convergence 2025
Development, Validation and Performance of a Questionnaire for Assessing the Knowledge Base of Primary Care Physicians About Management of Rheumatoid Arthritis and Impact of an Information Course
Background/Purpose: Long-term outcomes in rheumatic diseases are impacted by their timely diagnosis, institution of correct treatment, management of complications and rigorous joint preservation strategies. The…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 219
- Next Page »
